| System organ class
|
Very common (≥10%)
|
Common (1–10%)
|
Frequency unknownc
|
| Blood and lymphatic system disorders
|
Anemia; Leukopenia
|
Thrombocytopenia
|
|
| Immune system disorders
|
|
|
Hypersensitivity
|
| Metabolism and nutrition disorders
|
Fluid retention
|
|
|
| Psychiatric disorders
|
|
|
Confusional state; Depression
|
| Nervous system disorders
|
|
Lethargy; Headache
|
|
| Cardiac disorders
|
Congestive heart failure
|
Myocardial infarction
|
Myocardial ischemia
|
| Vascular disorders
|
|
Embolism
|
Hypertension
|
| Gastrointestinal disorders
|
Nauseab; Vomitingb; Diarrheab
|
|
|
| Hepatobiliary disorders
|
Abnormal hepatic function
|
|
|
| Skin and subcutaneous tissue disorders
|
|
|
Angioedemac; Allergic dermatitis
|
| Musculoskeletal and connective tissue disorders
|
|
|
Muscle weakness
|
| Reproductive system and breast disorders
|
Gynecomastia
|
|
Erectile dysfunction
|
| General disorders and administration site conditions
|
|
|
Injection site thrombosis (IVTooltip intravenous solution)
|
| Footnotes: a = Could not be estimated from available data. b = Especially during the first 2 weeks of therapy. c = Angioedema (Quincke edema, larynx edema) can occur. Often occurs in combination with ACE inhibitors. EMP should be immediately discontinued if angioedema occurs. Sources: [1]
|
